{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:22:31Z","timestamp":1790198551094,"version":"4.1.0"},"reference-count":152,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Thanks to advances in the field over the years, HIV\/AIDS has now become a manageable chronic condition. Nevertheless, a new set of HIV-associated complications has emerged, related in part to the accelerated ageing observed in people living with HIV\/AIDS, the cumulative toxicities from exposure to antiretroviral drugs over decades and emerging comorbidities. As a result, HIV\/AIDS can still have a negative impact on patients\u2019 quality of life (QoL). In this scenario, it is reasonable to believe that the concept of therapeutic success, traditionally associated with CD4 cell count restoration and HIV RNA plasma viral load suppression and the absence of drug resistances, needs to be redefined to include other factors that reach beyond antiretroviral efficacy. With this in mind, a group of experts initiated and coordinated the RET Project, and this group, using the available evidence and their clinical experience in the field, has proposed new criteria to redefine treatment success in HIV, arranged into five main concepts: rapid initiation, efficacy, simplicity, safety, and QoL. An extensive review of the literature was performed for each category, and results were discussed by a total of 32 clinicians with experience in HIV\/AIDS (4 coordinators + 28 additional experts). This article summarizes the conclusions of these experts and presents the most updated overview on the five topics, along with a discussion of the experts\u2019 main concerns, conclusions and\/or recommendations on the most controversial issues.<\/jats:p>","DOI":"10.1093\/jac\/dkab168","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T19:28:06Z","timestamp":1620415686000},"page":"2501-2518","source":"Crossref","is-referenced-by-count":29,"title":["Redefining therapeutic success in HIV patients: an expert view"],"prefix":"10.1093","volume":"76","author":[{"given":"Antonio","family":"Antela","sequence":"first","affiliation":[{"name":"Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[{"name":"Hospital Universitario Reina Sof\u00eda, Cordoba, Spain"},{"name":"Universidad de C\u00f3rdoba, Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba, C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M","family":"Llibre","sequence":"additional","affiliation":[{"name":"Hospital Universitari Germans Trias i Pujol, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, Universidad de Alcal\u00e1, IRYCIS, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the RET Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Antela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M","family":"Llibre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Alonso Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ram\u00f3n Blanco","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dalmau Juanola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"de la Fuente Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Due\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Jos\u00e9 Galindo Puerto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Garc\u00eda del Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"G\u00f3rgolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Hidalgo-Tenorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernando","family":"Knobel Freu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Carlos L\u00f3pez Bernaldo de Quir\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Mac\u00edas S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Mart\u00edn Ru\u00edz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Mart\u00ednez Chamorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Mas\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1ximo","family":"Miguelez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Miralles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Olalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban Ribera","family":"Pascuet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Rodr\u00edguez-Vidigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santos","family":"Jes\u00fas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"key":"2021091709024483900_dkab168-B1","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIVinfection as a chronic disease","volume":"382","author":"Deeks","year":"2013","journal-title":"Lancet"},{"key":"2021091709024483900_dkab168-B2","doi-asserted-by":"crossref","first-page":"18514","DOI":"10.1038\/s41598-019-54969-3","article-title":"Chronic disease onset among people living with HIV and AIDS in a large private insurance claims dataset","volume":"9","author":"Yang","year":"2019","journal-title":"Sci Rep"},{"key":"2021091709024483900_dkab168-B3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/infdis\/jiz678","article-title":"Loss of preexisting immunological memory among human immunodeficiency virus\u2013infected women despite immune reconstitution with antiretroviral therapy","volume":"222","author":"Thomas","year":"2020","journal-title":"J Infect Dis"},{"key":"2021091709024483900_dkab168-B4","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/S2214-109X(17)30451-5","article-title":"Prevalence of chronic obstructive pulmonary disease in the global population with HIV: a systematic review and meta-analysis","volume":"6","author":"Bigna","year":"2018","journal-title":"Lancet Glob Health"},{"key":"2021091709024483900_dkab168-B5","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1097\/QAD.0000000000001215","article-title":"Chronic health conditions in Medicare beneficiaries 65 years old, and older with HIV infection","volume":"30","author":"Friedman","year":"2016","journal-title":"AIDS"},{"key":"2021091709024483900_dkab168-B6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/cid\/ciy146","article-title":"Higher risk of abdominal obesity, elevated low-density lipoprotein cholesterol, and hypertriglyceridemia, but not of hypertension, in people living with human immunodeficiency virus (HIV): results from the Copenhagen comorbidity in HIV infection study","volume":"67","author":"Gelpi","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021091709024483900_dkab168-B7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0033354917748670","article-title":"Excess clinical comorbidity among HIV-infected patients accessing primary care in US community health centers","volume":"133","author":"Mayer","year":"2018","journal-title":"Public Health Rep"},{"key":"2021091709024483900_dkab168-B8","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/cid\/ciu701","article-title":"Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study","volume":"59","author":"Schouten","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2021091709024483900_dkab168-B9","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/S2352-3018(14)70003-7","article-title":"Quality of life in chronic HIV infection","volume":"1","author":"Pozniak","year":"2014","journal-title":"Lancet HIV"},{"key":"2021091709024483900_dkab168-B10","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2147\/PPA.S142643","article-title":"Patient preferences for antiretroviral therapy: effectiveness, quality of life, access and novel delivery methods","volume":"11","author":"Eaton","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"2021091709024483900_dkab168-B11","article-title":"Rapid initiation of antiretroviral therapy for people living with HIV","volume":"6","author":"Mateo-Urdiales","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2021091709024483900_dkab168-B12","doi-asserted-by":"crossref","first-page":"e1002357","DOI":"10.1371\/journal.pmed.1002357","article-title":"Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: a randomized unblinded trial","volume":"14","author":"Koenig","year":"2017","journal-title":"PLoS Med"},{"key":"2021091709024483900_dkab168-B13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QAD.0000000000001671","article-title":"Benefits and risks of rapid initiation of antiretroviral therapy","volume":"32","author":"Ford","year":"2018","journal-title":"AIDS"},{"key":"2021091709024483900_dkab168-B14","doi-asserted-by":"crossref","first-page":"ofy104","DOI":"10.1093\/ofid\/ofy104","article-title":"Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the Southern United States","volume":"5","author":"Colasanti","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2021091709024483900_dkab168-B15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0000000000002124","article-title":"RAPID antiretroviral therapy: High virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population","volume":"33","author":"Coffey","year":"2019","journal-title":"AIDS"},{"key":"2021091709024483900_dkab168-B16","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1093\/cid\/ciz1213","article-title":"Darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in a rapid initiation model of care for HIV-1 infection: primary analysis of the DIAMOND study","volume":"71","author":"Huhn","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021091709024483900_dkab168-B17","author":"Rolle"},{"key":"2021091709024483900_dkab168-B18"},{"key":"2021091709024483900_dkab168-B19"},{"key":"2021091709024483900_dkab168-B20"},{"key":"2021091709024483900_dkab168-B21"},{"key":"2021091709024483900_dkab168-B22","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society-USA panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"2021091709024483900_dkab168-B23","author":"Zuppelli"},{"key":"2021091709024483900_dkab168-B24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1086\/513823","article-title":"Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy","volume":"177","author":"Marschner","year":"1998","journal-title":"J Infect Dis"},{"key":"2021091709024483900_dkab168-B25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/00002030-199905070-00008","article-title":"The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs","volume":"13","author":"Murray","year":"1999","journal-title":"AIDS"},{"key":"2021091709024483900_dkab168-B26","author":"Ribaudo"},{"key":"2021091709024483900_dkab168-B27","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cid\/cit529","article-title":"Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation","volume":"57","author":"Laprise","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2021091709024483900_dkab168-B28","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/infdis\/jis104","article-title":"Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis","volume":"205","author":"Grennan","year":"2012","journal-title":"J Infect Dis"},{"key":"2021091709024483900_dkab168-B29","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jac\/dkl092","article-title":"HIV-1 viral load blips are of limited clinical significance","volume":"57","author":"Lee","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2021091709024483900_dkab168-B30","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1097\/QAD.0000000000000224","article-title":"Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals","volume":"28","year":"2014","journal-title":"AIDS"},{"key":"2021091709024483900_dkab168-B31","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1086\/590943","article-title":"Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials","volume":"47","author":"Gupta","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2021091709024483900_dkab168-B32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial","volume":"378","author":"Cohen","year":"2011","journal-title":"Lancet"},{"key":"2021091709024483900_dkab168-B33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"2021091709024483900_dkab168-B34","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/S0140-6736(14)61170-3","article-title":"Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001\/ANRS143 randomised non-inferiority trial","volume":"384","author":"Raffi","year":"2014","journal-title":"Lancet"},{"key":"2021091709024483900_dkab168-B35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2021091709024483900_dkab168-B36","doi-asserted-by":"crossref","first-page":"e1001510","DOI":"10.1371\/journal.pmed.1001510","article-title":"Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)","volume":"10","author":"Mocroft","year":"2013","journal-title":"PLoS Med"},{"key":"2021091709024483900_dkab168-B37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0140-6736(08)61697-9","article-title":"Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model","volume":"373","author":"Granich","year":"2009","journal-title":"Lancet"},{"key":"2021091709024483900_dkab168-B38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"2021091709024483900_dkab168-B39","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1600693","article-title":"Antiretroviral therapy for the prevention of HIV-1 transmission","volume":"375","author":"Cohen","year":"2016","journal-title":"N Engl J Med"},{"key":"2021091709024483900_dkab168-B40","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1186\/1471-2458-14-917","article-title":"The Opposites Attract Study of viral load, HIV treatment and HIV transmission in serodiscordant homosexual male couples: design and methods","volume":"14","author":"Bavinton","year":"2014","journal-title":"BMC Public Health"},{"key":"2021091709024483900_dkab168-B41","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","article-title":"Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study","volume":"393","author":"Rodger","year":"2019","journal-title":"Lancet"},{"key":"2021091709024483900_dkab168-B42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jama.2016.5148","article-title":"Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy","volume":"316","author":"Rodger","year":"2016","journal-title":"JAMA"},{"key":"2021091709024483900_dkab168-B43","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/QAD.0b013e3282f9b67a","article-title":"Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006","volume":"22","author":"Townsend","year":"2008","journal-title":"AIDS"},{"key":"2021091709024483900_dkab168-B44","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief report: dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021091709024483900_dkab168-B45","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"2021091709024483900_dkab168-B46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","article-title":"Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK","volume":"63","author":"Rockstroh","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021091709024483900_dkab168-B47","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M14-1084","article-title":"Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial","volume":"161","author":"Lennox","year":"2014","journal-title":"Ann Intern Med"},{"key":"2021091709024483900_dkab168-B48","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2021091709024483900_dkab168-B49","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2021091709024483900_dkab168-B50","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"2021091709024483900_dkab168-B51","author":"Cahn"},{"key":"2021091709024483900_dkab168-B52","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"2021091709024483900_dkab168-B53","author":"Cahn"},{"key":"2021091709024483900_dkab168-B54","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/00126334-200407010-00007","article-title":"Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence","volume":"36","author":"Stone","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021091709024483900_dkab168-B55","first-page":"34","article-title":"The Assessing Patients\u2019 Preferred Treatments (APPT-1) study","volume":"14 Suppl 1","author":"Moyle","year":"2003","journal-title":"Int J STD AIDS"},{"key":"2021091709024483900_dkab168-B56","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00126334-200403010-00006","article-title":"The impact of adherence on CD4 cell count responses among HIV-infected patients","volume":"35","author":"Wood","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021091709024483900_dkab168-B57","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1468-1293.2005.00287.x","article-title":"Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules","volume":"6","author":"Portsmouth","year":"2005","journal-title":"HIV Med"},{"key":"2021091709024483900_dkab168-B58","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/QAD.0000000000002384","article-title":"Antiretroviral therapy adherence among treatment-naive HIV-infected patients","volume":"34","author":"Chakraborty","year":"2020","journal-title":"AIDS"},{"key":"2021091709024483900_dkab168-B59","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2147\/PPA.S192735","article-title":"Adherence to HIV treatment regimens: systematic literature review and meta-analysis","volume":"13","author":"Altice","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"2021091709024483900_dkab168-B60","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12981-018-0204-0","article-title":"A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV","volume":"15","author":"Clay","year":"2018","journal-title":"AIDS Res Ther"},{"key":"2021091709024483900_dkab168-B61","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1086\/596482","article-title":"Better adherence with once-daily antiretroviral regimens: a meta-analysis","volume":"48","author":"Parienti","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2021091709024483900_dkab168-B62","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"2021091709024483900_dkab168-B63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/25787489.2019.1661696","article-title":"Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study","volume":"20","author":"Murray","year":"2019","journal-title":"HIV Res Clin Pract"},{"key":"2021091709024483900_dkab168-B64","author":"Swindells"},{"key":"2021091709024483900_dkab168-B65","year":"2020"},{"key":"2021091709024483900_dkab168-B66","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1","volume":"381","author":"Kouanfack","year":"2019","journal-title":"N Engl J Med"},{"key":"2021091709024483900_dkab168-B67","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2021091709024483900_dkab168-B68","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/cid\/ciy540","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial","volume":"68","author":"Orkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021091709024483900_dkab168-B69","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"2021091709024483900_dkab168-B70","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3018(16)30016-9","article-title":"Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study","volume":"3","author":"Squires","year":"2016","journal-title":"Lancet HIV"},{"key":"2021091709024483900_dkab168-B71","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","article-title":"Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"key":"2021091709024483900_dkab168-B72","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"2021091709024483900_dkab168-B73"},{"key":"2021091709024483900_dkab168-B74"},{"key":"2021091709024483900_dkab168-B75"},{"key":"2021091709024483900_dkab168-B76"},{"key":"2021091709024483900_dkab168-B77"},{"key":"2021091709024483900_dkab168-B78","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.eimc.2018.09.015","article-title":"Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain","volume":"37","author":"Knobel","year":"2019","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2021091709024483900_dkab168-B79","first-page":"1809","article-title":"Human immunodeficiency virus infection and diverse physical health outcomes: an umbrella review of meta-analyses of observational studies","volume":"15","author":"Grabovac","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021091709024483900_dkab168-B80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0000000000002207","article-title":"Management of Osteoporosis in Patients Living With HIV-A Systematic Review and Meta-analysis","volume":"83","author":"Starup-Linde","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021091709024483900_dkab168-B81","first-page":"92","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate - is there a true difference in safety?","volume":"20","author":"Pepperrell","year":"2019","journal-title":"HIV Med"},{"key":"2021091709024483900_dkab168-B82","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2055-6640(20)30312-5","article-title":"How safe is TDF\/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP","volume":"4","author":"Pilkington","year":"2018","journal-title":"J Virus Erad"},{"key":"2021091709024483900_dkab168-B83","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1681\/ASN.2017040468","article-title":"Kidney Disease in HIV: moving beyond HIV-Associated Nephropathy","volume":"28","author":"Jotwani","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2021091709024483900_dkab168-B84","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/ki.2014.167","article-title":"Advances in the pathogenesis of HIV-associated kidney diseases","volume":"86","author":"Ross","year":"2014","journal-title":"Kidney Int"},{"key":"2021091709024483900_dkab168-B85","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/QAD.0000000000002223","article-title":"Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials","volume":"33","author":"Gupta","year":"2019","journal-title":"AIDS"},{"key":"2021091709024483900_dkab168-B86","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jinf.2017.01.010","article-title":"Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate","volume":"74","author":"Hamzah","year":"2017","journal-title":"J Infect"},{"key":"2021091709024483900_dkab168-B87","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S2352-3018(20)30036-9","article-title":"HIV and cardiovascular disease","volume":"7","author":"So-Armah","year":"2020","journal-title":"Lancet HIV"},{"key":"2021091709024483900_dkab168-B88","doi-asserted-by":"crossref","first-page":"e012241","DOI":"10.1161\/JAHA.119.012241","article-title":"HIV infection and incidence of cardiovascular diseases: an analysis of a large healthcare database","volume":"8","author":"Alonso","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2021091709024483900_dkab168-B89","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1161\/CIR.0000000000000695","article-title":"Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association","volume":"140","author":"Feinstein","year":"2019","journal-title":"Circulation"},{"key":"2021091709024483900_dkab168-B90","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/QAI.0000000000001996","article-title":"Factors associated with excess myocardial infarction risk in HIV-infected adults: a systematic review and meta-analysis","volume":"81","author":"Rao","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021091709024483900_dkab168-B91","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/hiv.12639","article-title":"Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the data collection on adverse events of anti-HIV drugs (D:A:D) study","volume":"19","author":"Hatleberg","year":"2018","journal-title":"HIV Med"},{"key":"2021091709024483900_dkab168-B92","doi-asserted-by":"crossref","first-page":"l5674","DOI":"10.1136\/bmj.l5674","article-title":"Statins for primary prevention of cardiovascular disease","volume":"367","author":"Byrne","year":"2019","journal-title":"BMJ"},{"key":"2021091709024483900_dkab168-B93","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 HA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2021091709024483900_dkab168-B94","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2016.05.015","article-title":"Abacavir and cardiovascular disease: a critical look at the data","volume":"132","author":"Llibre","year":"2016","journal-title":"Antiviral Res"},{"key":"2021091709024483900_dkab168-B95","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jama.2019.10298","article-title":"Association of smoking cessation with subsequent risk of cardiovascular disease","volume":"322","author":"Duncan","year":"2019","journal-title":"JAMA"},{"key":"2021091709024483900_dkab168-B96","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1521\/aeap.2009.21.3_supp.40","article-title":"Impact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans","volume":"21","author":"Crothers","year":"2009","journal-title":"AIDS Educ Prev"},{"key":"2021091709024483900_dkab168-B97","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1521\/aeap.2009.21.3_supp.14","article-title":"Review: the need for smoking cessation among HIV-positive smokers","volume":"21","author":"Nahvi","year":"2009","journal-title":"AIDS Educ Prev"},{"key":"2021091709024483900_dkab168-B98","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40273-014-0243-x","article-title":"The epidemiology of obesity: a big picture","volume":"33","author":"Hruby","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"2021091709024483900_dkab168-B99","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2055-6640(20)30277-6","article-title":"Are new antiretroviral treatments increasing the risks of clinical obesity?","volume":"5","author":"Hill","year":"2019","journal-title":"J Virus Erad"},{"key":"2021091709024483900_dkab168-B100","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021091709024483900_dkab168-B101","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Eng J Med"},{"key":"2021091709024483900_dkab168-B102","doi-asserted-by":"crossref","first-page":"S846","DOI":"10.1093\/ofid\/ofaa515.1904","article-title":"Weight change in suppressed people with HIV (PWH) switched from either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)","volume":"7","author":"Sax","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2021091709024483900_dkab168-B103","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/hep.31040","article-title":"Attributable fractions of NAFLD for mortality in the United States: results from NHANES III with 27 years of follow-up","volume":"72","author":"Alvarez","year":"2019","journal-title":"Hepatology"},{"key":"2021091709024483900_dkab168-B104","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/QAD.0000000000001504","article-title":"Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection","volume":"31","author":"Maurice","year":"2017","journal-title":"AIDS"},{"key":"2021091709024483900_dkab168-B105","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"152","author":"Park","year":"2017","journal-title":"Gastroenterology"},{"key":"2021091709024483900_dkab168-B106","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/hiv.12799","article-title":"Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients","volume":"21","author":"Sebastiani","year":"2019","journal-title":"HIV Med"},{"key":"2021091709024483900_dkab168-B107","first-page":"31687","article-title":"Nonalcoholic steatohepatitis: current thinking from the division of hepatology and nutrition at the food and drug administration","author":"Anania","year":"2020","journal-title":"Hepatology"},{"key":"2021091709024483900_dkab168-B108","article-title":"Increased prevalence of liver fibrosis in people living with HIV without viral hepatitis compared to population controls","author":"Kirkegaard-Klitbo","year":"2020","journal-title":"J Infect Dis"},{"key":"2021091709024483900_dkab168-B109","doi-asserted-by":"crossref","first-page":"4","DOI":"10.24875\/AIDSRev.19000023","article-title":"Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors","volume":"21","author":"Hoffmann","year":"2019","journal-title":"AIDS Rev"},{"key":"2021091709024483900_dkab168-B110","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s40264-016-0440-y","article-title":"Neuropsychiatric effects of HIV antiviral medications","volume":"39","author":"Treisman","year":"2016","journal-title":"Drug Saf"},{"key":"2021091709024483900_dkab168-B111","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrurol.2013.314","article-title":"Male sexual dysfunction and HIV-a clinical perspective","volume":"11","author":"Santi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"2021091709024483900_dkab168-B112","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/QAD.0000000000001348","article-title":"HIV and hypogonadism: a new challenge for young-aged and middle-aged men on effective antiretroviral therapy","volume":"31","author":"Lach\u00e2tre","year":"2017","journal-title":"AIDS"},{"key":"2021091709024483900_dkab168-B113","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/QAD.0000000000001756","article-title":"Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals","volume":"32","author":"Justice","year":"2018","journal-title":"AIDS"},{"key":"2021091709024483900_dkab168-B114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15284336.2017.1404690","article-title":"Frequency and severity of potential drug interactions in a cohort of HIV-infected patients identified through a multidisciplinary team","volume":"19","author":"Molas","year":"2018","journal-title":"HIV Clin Trials"},{"key":"2021091709024483900_dkab168-B115"},{"key":"2021091709024483900_dkab168-B116","doi-asserted-by":"crossref","first-page":"e0203890","DOI":"10.1371\/journal.pone.0203890","article-title":"Prevalence and trends of polypharmacy among HIV-positive and -negative men in the multicenter AIDS cohort study from 2004 to 2016","volume":"13","author":"Ware","year":"2018","journal-title":"PloS One"},{"key":"2021091709024483900_dkab168-B117"},{"key":"2021091709024483900_dkab168-B118","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1089\/apc.2017.0263","article-title":"Sexualized drug use (chemsex) is associated with high-risk sexual behaviors and sexually transmitted infections in HIV-positive men who have sex with men: data from the U-SEX GESIDA 9416 study","volume":"32","author":"Gonzalez-Baeza","year":"2018","journal-title":"AIDS Patient Care STDS"},{"key":"2021091709024483900_dkab168-B119","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S2352-3018(18)30065-1","article-title":"The finding of casual sex partners on the internet, methamphetamine use for sexual pleasure, and incidence of HIV infection among men who have sex with men in Bangkok, Thailand: an observational cohort study","volume":"5","author":"Piyaraj","year":"2018","journal-title":"Lancet HIV"},{"key":"2021091709024483900_dkab168-B120"},{"key":"2021091709024483900_dkab168-B121","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12916-016-0640-4","article-title":"Beyond viral suppression of HIV - the new quality of life frontier","volume":"14","author":"Lazarus","year":"2016","journal-title":"BMC Med"},{"key":"2021091709024483900_dkab168-B122","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/COH.0000000000000583","article-title":"Fast-Track Cities: striving to end urban HIV epidemics by 2030","volume":"14","author":"Duncombe","year":"2019","journal-title":"Curr Opin HIV AIDS"},{"key":"2021091709024483900_dkab168-B123","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12955-017-0778-6","article-title":"Measuring quality of life among people living with HIV: a systematic review of reviews","volume":"15","author":"Cooper","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"2021091709024483900_dkab168-B124"},{"key":"2021091709024483900_dkab168-B125","author":"Bristowe"},{"key":"2021091709024483900_dkab168-B126","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/QAI.0b013e318245cafe","article-title":"The development of PROQOL-HIV: an international instrument to assess the health-related quality of life of persons living with HIV\/AIDS","volume":"59","author":"Duracinsky","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021091709024483900_dkab168-B127","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/2229-3485.86879","article-title":"Patient-reported outcomes: a new era in clinical research","volume":"2","author":"Deshpande","year":"2011","journal-title":"Perspect Clin Res"},{"key":"2021091709024483900_dkab168-B128","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/cer-2015-0014","article-title":"Framework and guidance for implementing patient-reported outcomes in clinical practice: evidence, challenges and opportunities","volume":"5","author":"Porter","year":"2016","journal-title":"J Comp Eff Res"},{"key":"2021091709024483900_dkab168-B129","doi-asserted-by":"crossref","first-page":"45","DOI":"10.11124\/JBISRIR-2016-002982","article-title":"Patient-reported and proxy-reported outcome measures for the assessment of health-related quality of life among patients receiving enteral feeding: a systematic review protocol","volume":"14","author":"Simpelaere","year":"2016","journal-title":"JBI Database System Rev Implement Rep"},{"key":"2021091709024483900_dkab168-B130"},{"key":"2021091709024483900_dkab168-B131","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1007\/s11136-013-0390-0","article-title":"Does providing feedback on patient-reported outcomes to healthcare professionals result in better outcomes for patients? A systematic review","volume":"22","author":"Boyce","year":"2013","journal-title":"Qual Life Res"},{"key":"2021091709024483900_dkab168-B132","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1001\/jama.2010.870","article-title":"Gaps in knowledge in caring for HIV survivors long-term","volume":"304","author":"Buscher","year":"2010","journal-title":"JAMA"},{"key":"2021091709024483900_dkab168-B133","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11136-008-9430-6","article-title":"The applications of PROs in clinical practice: what are they, do they work, and why?","volume":"18","author":"Greenhalgh","year":"2009","journal-title":"Qual Life Res"},{"key":"2021091709024483900_dkab168-B134","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1477-7525-11-164","article-title":"Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: A 10-year review","volume":"11","author":"Simpson","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"2021091709024483900_dkab168-B135","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12955-019-1208-8","article-title":"Assessing quality of life in people with HIV in Spain: psychometric testing of the Spanish version of WHOQOL-HIV-BREF","volume":"17","author":"Fuster-Ruiz de Apodaca","year":"2019","journal-title":"Health Qual Life Outcomes"},{"key":"2021091709024483900_dkab168-B136","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1089\/apc.2009.0259","article-title":"Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF","volume":"24","author":"Hodder","year":"2010","journal-title":"AIDS Patient Care STDS"},{"key":"2021091709024483900_dkab168-B137","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2174\/1570162X17666190212163518","article-title":"Real world patient-reported outcomes in HIV-infected adults switching to eviplera(r), because of a previous intolerance to cART. PRO-STR study","volume":"16","author":"Podzamczer","year":"2018","journal-title":"Curr HIV Res"},{"key":"2021091709024483900_dkab168-B138","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hiv.12440","article-title":"Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens","volume":"17 Suppl 5","author":"Raffi","year":"2016","journal-title":"HIV Med"},{"key":"2021091709024483900_dkab168-B139","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/infdis\/jir505","article-title":"Abacavir\/lamivudine versus tenofovir df\/emtricitabine as part of combination regimens for initial treatment of HIV: Final results","volume":"204","author":"Sax","year":"2011","journal-title":"J Infect Dis"},{"key":"2021091709024483900_dkab168-B140","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hiv.12468","article-title":"Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients","volume":"18","author":"Hoffmann","year":"2017","journal-title":"HIV Med"},{"key":"2021091709024483900_dkab168-B141","author":"Llibre"},{"key":"2021091709024483900_dkab168-B142","author":"Quercia"},{"key":"2021091709024483900_dkab168-B143","author":"Viswanathan","year":"2017"},{"key":"2021091709024483900_dkab168-B144","author":"Wohl"},{"key":"2021091709024483900_dkab168-B145","author":"Yagura"},{"key":"2021091709024483900_dkab168-B146","author":"Hsu","year":"2017"},{"key":"2021091709024483900_dkab168-B147","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s40271-018-0322-8","article-title":"Patient-reported symptoms over 48 weeks among participants in randomized, double-blind, phase III non-inferiority trials of adults with HIV on co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus co-formulated abacavir, dolutegravir, and lamivudine","volume":"11","author":"Wohl","year":"2018","journal-title":"Patient"},{"key":"2021091709024483900_dkab168-B148","author":"Wohl"},{"key":"2021091709024483900_dkab168-B149","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.2196\/jmir.9284","article-title":"The use and effects of electronic health tools for patient self-monitoring and reporting of outcomes following medication use: systematic review","volume":"20","author":"Lancaster","year":"2018","journal-title":"J Med Internet Res"},{"key":"2021091709024483900_dkab168-B150","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1080\/09540121.2016.1189501","article-title":"Provider perceptions of the value of same-day, electronic patient-reported measures for use in clinical HIV care","volume":"28","author":"Fredericksen","year":"2016","journal-title":"AIDS Care"},{"key":"2021091709024483900_dkab168-B151","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1097\/MLR.0000000000001061","article-title":"Options for the interpretation of and recommendations for acting on different PROMs in daily clinical practice using KLIK","volume":"57 Suppl 5 Suppl 1","author":"Haverman","year":"2019","journal-title":"Med Care"},{"key":"2021091709024483900_dkab168-B152","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/S2352-3018(19)30343-1","article-title":"Stigma reduction interventions in people living with HIV to improve health-related quality of life","volume":"7","author":"Andersson","year":"2019","journal-title":"Lancet HIV"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/10\/2501\/40394464\/dkab168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/10\/2501\/40394464\/dkab168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T09:06:19Z","timestamp":1631869579000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/10\/2501\/6291134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":152,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,6,2]]},"published-print":{"date-parts":[[2021,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab168","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,6,2]]}}}